Sector News

Abbott plunges deeper into diagnostics with $5.8bn Alere buy

February 2, 2016
Life sciences

Abbott is delving deeper into diagnostics with a definitive deal to buy test-maker Alere for around $5.8 billion.

Alere’s portfolio of products provides Abbott with access to new channels and geographies, including entry into fast-growing outlets, such as doctors’ offices, clinics, pharmacies and at-home testing, the firm noted.

The US drug giant said the move will see it become the leading diagnostics provider of point of care testing, with total diagnostics sales overshooting $7 billion after the transaction closes.

The move is expected to be immediately accretive to Abbott’s ongoing earnings per share upon close and significantly accretive thereafter, with around 12-13 cents added in 2017 and more than 20 cents in 2018. The combination is also expected to generate annual pre-tax synergies near $500 million by 2019 and increasing thereafter.

“The combination of Alere and Abbott will create the world’s premier point of care testing business and significantly strengthen and grow Abbott’s diagnostics presence,” said Miles White, Abott’s chairman and chief executive. “We want to offer our customers the best and broadest diagnostics solutions. Alere helps us do that.”

News of the deal comes shortly after Abbott posted a 15% drop in profit for the fourth quarter of the year, largely because of exchange rate effects.

By Selina McKee

Source: Pharma Times

Related News

June 13, 2021

Making drug-resistant bacteria susceptible to antibiotics

Life sciences

Antibiotic resistance remains one of the biggest public health challenges. New drugs are still needed to tackle tough-to-treat bacteria. But finding new therapeutics to kill off pathogenic bacteria has been difficult.

June 13, 2021

Vexed by vectors: How COVID-19 vaccine and cell and gene players are tackling the viral vector bottleneck

Life sciences

Viral vectors are engineered viruses used to deliver gene therapies, gene-modified cell therapies and certain vaccines. And their shortage is already upon us, thanks to manufacturing approaches that simply haven’t kept pace with the advance of cell and gene therapies.

June 13, 2021

Beigene expands into cancer cell therapy with Shoreline pact

Life sciences

Beigene, a fast-growing drugmaker based in Cambridge, Massachusetts and Beijing, will partner with Shoreline Biosciences to develop cell therapies for cancer, expanding its research beyond the small molecule and antibody drugs.

Send this to a friend